July 15, 2025

Figure 2 from First-in-Human Phase I/IIa Study of the First-in-Class CDK2/4/6 Inhibitor PF-06873600 Alone or with Endocrine Therapy in Patients with Breast Cancer

Key Points

Main finding shows distinct plasma concentration profiles for PF-06873600 in patients with breast cancer.
Key evidence indicates median plasma levels measured after single and multiple oral doses on specific days.
Approach involves tracking concentration-time profiles for both immediate and modified release formulations.
Significance lies in optimizing treatment strategies for breast cancer through understanding drug kinetics.

Abstract

Median plasma PF-06873600 concentration–time profile. A, Following single oral doses on cycle 1 day 1. B, Following multiple oral doses on cycle 1 day 15. *Part 1 PF-06873600 25 mg twice daily (BID) IR combined with part 1A PF-06873600 25 mg BID IR, part 1A PF-06873600 25 mg BID biomarker, and part 1C PF-06873600 MR 20 mg lead-in IR 25 mg BID. IR, immediate release; MR, modified release.

Figure 2 from First-in-Human Phase I/IIa Study of the First-in-Class CDK2/4/6 Inhibitor PF-06873600 Alone or with Endocrine Therapy in Patients with Breast Cancer

Key Points

Abstract

Cite This Study